Overview

Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee

Status:
Withdrawn
Trial end date:
2009-05-01
Target enrollment:
0
Participant gender:
All
Summary
This study will assess the safety and efficacy of zoledronic acid in patients presenting with spontaneous osteonecrosis of the knee.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Treatments:
Diphosphonates
Zoledronic Acid
Criteria
Inclusion Criteria:

- Adults 40-85 years of age

- Diagnosis of painful osteonecrosis of the knee within the last month.

Exclusion Criteria:

- Intravenous (iv) bisphosphonates within the last 2 years.

- Abnormal thyroid, kidney or liver function.

- Abnormal blood calcium or alkaline phosphatase levels.

Other protocol-defined inclusion/exclusion criteria may apply